Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd (CGEN) is a clinical-stage cancer immunotherapy company that regularly issues news on its drug discovery platform, clinical programs, and strategic collaborations. The company emphasizes its predictive AI/ML-powered computational discovery platform, Unigen™, which it uses to identify novel drug targets and biological pathways for immuno-oncology therapies.
News about Compugen often highlights progress across its key clinical-stage assets. Updates include data and trial milestones for COM701, a potential first-in-class anti-PVRIG Fc-reduced antibody, and COM902, a potential best-in-class Fc-reduced high-affinity anti-TIGIT antibody in Phase 1 development. The company also reports on GS-0321 (previously COM503), a potential first-in-class, high-affinity anti-IL-18 binding protein antibody licensed to Gilead, and on rilvegostomig, a PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca under license from Compugen.
Investors following CGEN news can expect coverage of clinical trial initiations and updates, such as the MAIA-ovarian platform trial evaluating COM701 maintenance therapy in relapsed platinum-sensitive ovarian cancer, pooled analyses of Phase 1 trials in platinum-resistant ovarian cancer, and first-in-human studies of GS-0321 in advanced solid malignancies. Company communications also describe partner-led studies of rilvegostomig in indications including non-small cell lung cancer and bladder cancer.
In addition, Compugen’s news flow includes quarterly financial results, cash runway commentary, amendments to collaboration agreements such as royalty monetization transactions with AstraZeneca, and participation in scientific and investor conferences. The CGEN news page on Stock Titan aggregates these announcements so readers can track clinical, financial, and partnership developments from a single source.
Compugen Ltd. (CGEN) reported preliminary results from its Phase 1 dose escalation study of COM902, an anti-TIGIT antibody, for patients with advanced solid tumors, during the 36th Annual Meeting of the Society for Immunotherapy of Cancer. The study involved 18 heavily pretreated patients, achieving a 50% disease control rate. COM902 was well tolerated, with no maximum tolerated dose reached. The recommended dose for expansion is 3 mg/kg IV Q3W. Future studies will combine COM902 with COM701 to explore new therapeutic options.
Compugen Ltd. (Nasdaq: CGEN) announced a significant collaboration expansion with Bristol Myers Squibb (NYSE: BMY), which completed a $20 million investment in Compugen. This investment involved purchasing 2,332,815 shares at $8.57333 each, a 33% premium over the November 9, 2021 closing price. A new joint steering committee will oversee programs under the collaboration, aiming to advance clinical studies. Compugen's lead candidate, COM701, targets immune checkpoints in cancer therapy, showcasing its potential to enhance T cell activation in tumor environments.
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy firm, announced its participation in several upcoming investor conferences. Notable events include the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 11:20 AM ET, and the Jefferies Virtual Healthcare Conference on November 18, 2021, with a recording available from 3:00 AM ET. Additional engagements include the Truist Securities SITC Breakfast on November 13, JMP Securities Virtual C-Suite on November 29, and the JMP Securities Virtual Hematology Oncology Summit on December 7. For more details, visit www.cgen.com.
Compugen Ltd. (NASDAQ: CGEN) will release its third quarter 2021 financial results on November 12, 2021, before U.S. markets open. A conference call and webcast will follow at 8:30 AM ET to discuss the results and provide a corporate update. Additionally, Compugen will present data at the Society for Immunotherapy of Cancer Annual Meeting from November 10-14, 2021, with eposters available on the same day as the earnings release. Compugen focuses on cancer immunotherapy, with lead candidates COM701 and COM902 in Phase 1 studies.
Compugen Ltd. (NASDAQ: CGEN) announced a $6 million milestone payment from AstraZeneca (NASDAQ: AZN) following the first patient dosing in a Phase 1/2 study of AZD2936, a TIGIT/PD-1 bispecific antibody for lung cancer. This event marks the advancement of Compugen's COM902 program into clinical trials, contributing to its pipeline expansion. To date, Compugen has received a total of $12 million from AstraZeneca under their 2018 license agreement, which could potentially yield up to $200 million in milestone payments and royalties on sales.
Compugen Ltd. (NASDAQ: CGEN) announced the presentation of new clinical and preclinical data at the 36th Annual Meeting of the Society for Immunotherapy of Cancer, scheduled for November 10-14, 2021. Key presentations include the evaluation of COM902, an anti-TIGIT antibody, in patients with advanced solid tumors, and the results of COM701 in combination with other therapies. Both studies emphasize safety, tolerability, and pharmacokinetics. Compugen continues to advance its lead product candidates in cancer immunotherapy, as they navigate through Phase 1 studies.
Compugen Ltd. (NASDAQ: CGEN) announced that it will present at the Cantor Global Healthcare Conference on September 30, 2021, at 1:20 pm ET. The presentation will cover its advancements in cancer immunotherapy, particularly focusing on COM701, an anti-PVRIG antibody, and COM902, targeting TIGIT. Both are in Phase 1 studies for treating solid and hematological tumors. A live webcast will be accessible via Compugen's website.
Compugen Ltd. (NASDAQ: CGEN) will present at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 11:00 am ET. The presentation will be available via a live webcast on Compugen's website, with a replay accessible afterward.
Compugen is focused on cancer immunotherapy, with key products like COM701 and COM902 in Phase 1 studies. Based in Israel, the company utilizes predictive discovery platforms to create novel drug targets.
Compugen Ltd. (NASDAQ: CGEN) announced the advancement of a bispecific antibody derived from COM902 into clinical development by AstraZeneca, which will evaluate AZD2936 in patients with advanced non-small cell lung cancer. AstraZeneca holds exclusive rights for the development of products based on COM902, while Compugen retains rights for monotherapies and combination treatments. Compugen has received a $10 million upfront payment and $2 million in milestone payments, with a potential of up to $200 million in future milestones.
Compugen Ltd. (NASDAQ: CGEN) released its financial results for Q2 2021, reporting a net loss of $9.5 million, up from $6.2 million in Q2 2020. R&D expenses rose to $6.8 million from $4.4 million year-over-year. Compugen initiated three clinical studies for its anti-PVRIG, anti-TIGIT, and anti-PD-1 combination therapies, highlighting its leadership in the DNAM axis space. Cash and equivalents totaled approximately $111 million as of June 30, 2021. Upcoming data readouts are expected to enhance the company's clinical data foundation.